Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Jennifer Diamond

Concepts (284)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Triple Negative Breast Neoplasms
16
2024
188
6.700
 Why?
Breast Neoplasms
23
2023
2139
4.390
 Why?
Immunoconjugates
7
2023
101
2.620
 Why?
Antineoplastic Agents
23
2023
2078
2.590
 Why?
Antineoplastic Combined Chemotherapy Protocols
19
2023
1579
2.460
 Why?
Pyrimidines
9
2021
448
2.400
 Why?
Receptor, ErbB-2
11
2023
337
1.940
 Why?
Protein Kinase Inhibitors
10
2022
883
1.730
 Why?
Piperazines
4
2020
334
1.700
 Why?
Paclitaxel
6
2022
216
1.620
 Why?
Camptothecin
9
2023
107
1.610
 Why?
Neoplasms
14
2022
2467
1.600
 Why?
Pyrazoles
6
2021
406
1.400
 Why?
Quinoxalines
2
2020
65
1.320
 Why?
Antibodies, Monoclonal, Humanized
10
2024
763
1.290
 Why?
Azepines
3
2020
89
1.250
 Why?
Ovarian Neoplasms
4
2020
488
1.220
 Why?
Histone Deacetylase Inhibitors
4
2024
207
1.210
 Why?
Cyclin-Dependent Kinase 4
2
2018
42
1.110
 Why?
Cyclin-Dependent Kinase 6
2
2018
39
1.100
 Why?
Neutropenia
4
2022
135
0.890
 Why?
Gene Expression Regulation, Neoplastic
5
2020
1341
0.790
 Why?
Xenograft Model Antitumor Assays
11
2021
815
0.760
 Why?
beta Catenin
2
2020
223
0.760
 Why?
Breast Neoplasms, Male
2
2018
29
0.740
 Why?
Female
49
2024
68842
0.700
 Why?
Cancer Care Facilities
1
2020
31
0.700
 Why?
Chemotherapy, Adjuvant
4
2023
383
0.690
 Why?
Maximum Tolerated Dose
9
2022
196
0.690
 Why?
Benzoxazoles
1
2020
20
0.690
 Why?
Receptors, Estrogen
3
2021
429
0.680
 Why?
Carcinoma, Lobular
2
2018
48
0.680
 Why?
eIF-2 Kinase
1
2019
30
0.650
 Why?
Lymphocytes, Tumor-Infiltrating
2
2020
209
0.640
 Why?
Tumor Microenvironment
4
2024
616
0.640
 Why?
Anthracyclines
3
2023
46
0.610
 Why?
Humans
62
2024
130305
0.600
 Why?
Taxoids
3
2023
98
0.600
 Why?
Drug Resistance, Neoplasm
4
2020
755
0.580
 Why?
Wnt Signaling Pathway
1
2019
169
0.580
 Why?
Carcinoma, Ductal, Breast
1
2018
82
0.570
 Why?
Aurora Kinase A
4
2020
55
0.570
 Why?
Trastuzumab
4
2023
100
0.560
 Why?
Aged
22
2023
22282
0.560
 Why?
Pyrazines
2
2018
89
0.540
 Why?
Colonic Neoplasms
1
2018
237
0.520
 Why?
Myocardial Infarction
1
2023
1036
0.520
 Why?
Pyridines
2
2018
474
0.510
 Why?
Tumor Suppressor Protein p53
4
2024
513
0.500
 Why?
Neoadjuvant Therapy
1
2018
387
0.490
 Why?
Nuclear Proteins
2
2023
652
0.490
 Why?
Angiopoietin-1
1
2015
11
0.490
 Why?
Angiopoietin-2
1
2015
15
0.490
 Why?
Uterine Cervical Neoplasms
1
2017
234
0.450
 Why?
Medicare
4
2023
740
0.440
 Why?
Cell Line, Tumor
9
2022
3185
0.440
 Why?
Colorectal Neoplasms
5
2022
733
0.430
 Why?
Middle Aged
23
2021
31322
0.420
 Why?
Antibodies, Monoclonal
4
2024
1372
0.410
 Why?
Dose-Response Relationship, Drug
6
2022
1983
0.410
 Why?
Tumor Suppressor Proteins
1
2015
315
0.400
 Why?
Cell Proliferation
8
2020
2381
0.400
 Why?
Proto-Oncogene Proteins c-met
1
2013
75
0.400
 Why?
Antineoplastic Agents, Immunological
3
2019
174
0.400
 Why?
Recombinant Fusion Proteins
1
2015
645
0.390
 Why?
Point Mutation
1
2013
227
0.390
 Why?
Adult
24
2024
35711
0.390
 Why?
Treatment Outcome
12
2022
10341
0.380
 Why?
Triazoles
1
2013
155
0.380
 Why?
Angiogenesis Inhibitors
3
2018
223
0.370
 Why?
Mice, Nude
6
2020
688
0.360
 Why?
Carcinoma, Renal Cell
1
2013
181
0.360
 Why?
Mitochondria
1
2017
857
0.350
 Why?
Clinical Trials, Phase I as Topic
2
2020
50
0.350
 Why?
Neoplasm Recurrence, Local
4
2021
959
0.340
 Why?
Histones
3
2023
589
0.340
 Why?
Heart Failure
1
2023
2164
0.340
 Why?
Neoplasm Metastasis
4
2020
615
0.340
 Why?
Genes, BRCA2
1
2009
24
0.340
 Why?
Genes, BRCA1
1
2009
32
0.330
 Why?
Biomarkers, Tumor
2
2014
1196
0.330
 Why?
BRCA2 Protein
1
2009
53
0.320
 Why?
Molecular Targeted Therapy
3
2019
389
0.320
 Why?
Aged, 80 and over
8
2020
7128
0.320
 Why?
Thrombophilia
1
2009
68
0.320
 Why?
Pregnancy Complications, Neoplastic
1
2009
52
0.310
 Why?
Neoplasm Staging
5
2021
1294
0.310
 Why?
Lung Neoplasms
2
2024
2376
0.310
 Why?
Kidney Neoplasms
1
2013
352
0.310
 Why?
Quinolines
2
2021
149
0.300
 Why?
Apoptosis
7
2024
2519
0.300
 Why?
Aromatase Inhibitors
2
2018
52
0.300
 Why?
Receptors, Progesterone
2
2021
345
0.290
 Why?
DNA-Binding Proteins
1
2015
1433
0.280
 Why?
Mice
9
2021
16832
0.270
 Why?
Models, Biological
1
2014
1716
0.260
 Why?
Doxorubicin
3
2024
321
0.250
 Why?
Liver Neoplasms
1
2009
643
0.220
 Why?
Cyclophosphamide
2
2018
232
0.220
 Why?
Radiosurgery
2
2019
316
0.220
 Why?
Disease Models, Animal
3
2021
4044
0.210
 Why?
United States
5
2023
14110
0.210
 Why?
Animals
11
2021
35076
0.200
 Why?
Cyclin-Dependent Kinase 9
1
2022
10
0.200
 Why?
Biopsy
2
2018
1107
0.200
 Why?
Histone Deacetylase 1
1
2022
22
0.200
 Why?
Aurora Kinases
2
2012
29
0.190
 Why?
Administration, Oral
3
2022
788
0.190
 Why?
G2 Phase Cell Cycle Checkpoints
3
2022
46
0.190
 Why?
Disease Progression
4
2019
2639
0.190
 Why?
Topoisomerase I Inhibitors
2
2022
17
0.190
 Why?
Fluorouracil
1
2022
201
0.190
 Why?
Acetylation
1
2022
237
0.180
 Why?
Biliary Tract Neoplasms
1
2021
25
0.180
 Why?
Arrhythmias, Cardiac
1
2023
318
0.180
 Why?
Androstadienes
1
2021
107
0.180
 Why?
Diarrhea
2
2019
179
0.180
 Why?
Carboplatin
1
2021
140
0.180
 Why?
Heterografts
1
2021
129
0.180
 Why?
Necrosis
2
2019
236
0.170
 Why?
Hospitals, University
1
2021
177
0.170
 Why?
Drug Administration Schedule
3
2017
766
0.170
 Why?
Fatigue
2
2022
322
0.170
 Why?
Histone Deacetylases
1
2022
211
0.170
 Why?
Immunotherapy
2
2023
599
0.170
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
59
0.170
 Why?
Male
13
2021
63748
0.170
 Why?
Clinical Trials as Topic
3
2016
1015
0.170
 Why?
Benzodiazepines
1
2021
133
0.170
 Why?
Immune System
1
2021
176
0.160
 Why?
Mechanistic Target of Rapamycin Complex 1
1
2020
116
0.160
 Why?
Myeloid Cell Leukemia Sequence 1 Protein
1
2019
43
0.160
 Why?
Kaplan-Meier Estimate
1
2021
869
0.160
 Why?
Tumor Cells, Cultured
1
2020
937
0.150
 Why?
Albumins
1
2019
103
0.150
 Why?
Maintenance Chemotherapy
1
2018
22
0.150
 Why?
Aquaporin 4
1
2019
95
0.150
 Why?
Vascular Endothelial Growth Factor A
2
2018
533
0.150
 Why?
Aminopyridines
1
2018
96
0.150
 Why?
Nausea
1
2018
109
0.150
 Why?
Antibodies, Bispecific
1
2018
49
0.150
 Why?
Mice, Inbred BALB C
1
2020
1245
0.140
 Why?
Breast
1
2018
152
0.140
 Why?
Drug Therapy, Combination
1
2020
1028
0.140
 Why?
Radiotherapy, Adjuvant
1
2018
213
0.140
 Why?
Purines
1
2018
170
0.140
 Why?
Mastectomy
1
2018
130
0.140
 Why?
Benzimidazoles
1
2018
160
0.140
 Why?
Topotecan
1
2017
12
0.140
 Why?
Isoflavones
1
2017
25
0.140
 Why?
Imidazoles
1
2018
231
0.140
 Why?
Calcium-Binding Proteins
1
2018
215
0.140
 Why?
Survival Analysis
1
2020
1293
0.140
 Why?
Carbolines
1
2017
27
0.140
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2017
19
0.140
 Why?
Programmed Cell Death 1 Receptor
1
2019
227
0.140
 Why?
Inhibitory Concentration 50
2
2016
83
0.130
 Why?
Nanoparticles
1
2021
370
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
71
0.130
 Why?
Cell Survival
1
2019
1098
0.130
 Why?
Insulin-Like Growth Factor I
1
2018
308
0.130
 Why?
Hypertension
2
2018
1245
0.130
 Why?
GPI-Linked Proteins
1
2016
67
0.130
 Why?
Adaptor Proteins, Signal Transducing
1
2018
398
0.120
 Why?
Neoplasms, Second Primary
1
2016
109
0.120
 Why?
Tumor Protein p73
1
2015
14
0.120
 Why?
Antibodies, Neoplasm
1
2015
35
0.120
 Why?
Carcinoma, Non-Small-Cell Lung
1
2024
1069
0.120
 Why?
Phosphorylation
1
2019
1709
0.120
 Why?
Hodgkin Disease
1
2016
136
0.120
 Why?
Risk Reduction Behavior
1
2016
212
0.120
 Why?
Retrospective Studies
3
2021
14675
0.120
 Why?
Maytansine
1
2014
16
0.110
 Why?
Demography
1
2015
281
0.110
 Why?
Brain Edema
1
2014
61
0.110
 Why?
Drug Interactions
1
2015
370
0.110
 Why?
Protein Kinases
1
2015
307
0.110
 Why?
Survival Rate
2
2019
1904
0.110
 Why?
Randomized Controlled Trials as Topic
1
2019
1381
0.110
 Why?
Threonine
1
2013
44
0.110
 Why?
Sulfones
1
2014
109
0.110
 Why?
Glycine
1
2014
166
0.100
 Why?
Drug Evaluation, Preclinical
1
2013
174
0.100
 Why?
Tumor Stem Cell Assay
1
2012
32
0.100
 Why?
Analgesics, Opioid
1
2021
921
0.100
 Why?
Time Factors
2
2020
6615
0.100
 Why?
Drug Design
1
2013
157
0.100
 Why?
Methionine
1
2013
159
0.100
 Why?
Heterozygote
1
2013
270
0.100
 Why?
Disease-Free Survival
1
2014
658
0.100
 Why?
In Situ Hybridization, Fluorescence
1
2013
323
0.100
 Why?
Treatment Failure
1
2013
351
0.100
 Why?
Neovascularization, Pathologic
1
2013
302
0.090
 Why?
Computational Biology
1
2015
600
0.090
 Why?
Cell Transformation, Neoplastic
1
2013
328
0.090
 Why?
Cluster Analysis
1
2012
485
0.090
 Why?
Carcinoma in Situ
1
2011
45
0.090
 Why?
Cellular Senescence
1
2012
177
0.090
 Why?
Risk Assessment
1
2020
3310
0.090
 Why?
Receptor Protein-Tyrosine Kinases
1
2013
237
0.090
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2010
86
0.090
 Why?
Colorado
1
2020
4471
0.090
 Why?
Mutation
2
2012
3723
0.080
 Why?
Sequence Analysis, DNA
1
2013
780
0.080
 Why?
Brain Neoplasms
2
2019
1149
0.080
 Why?
Tumor Burden
1
2010
285
0.080
 Why?
Pregnancy Trimester, Second
1
2009
76
0.080
 Why?
Keratinocytes
1
2010
244
0.080
 Why?
Mastectomy, Segmental
1
2009
85
0.080
 Why?
Pregnancy Trimester, First
1
2009
135
0.080
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
1
2009
90
0.080
 Why?
Apoptosis Regulatory Proteins
1
2009
183
0.080
 Why?
Lymph Node Excision
1
2009
168
0.070
 Why?
Infusions, Intravenous
2
2019
395
0.070
 Why?
Risk
1
2009
873
0.070
 Why?
Cell Adhesion Molecules
2
2019
177
0.070
 Why?
Risk Factors
1
2020
9865
0.070
 Why?
Prognosis
2
2018
3830
0.070
 Why?
Gene Expression Profiling
1
2012
1714
0.060
 Why?
Cell Cycle Proteins
2
2023
585
0.060
 Why?
Antigens, Neoplasm
2
2019
311
0.060
 Why?
CD8-Positive T-Lymphocytes
2
2023
842
0.060
 Why?
Cell Cycle
2
2018
587
0.060
 Why?
Combined Modality Therapy
2
2019
1219
0.050
 Why?
Mesylates
1
2022
7
0.050
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2022
65
0.050
 Why?
Signal Transduction
2
2014
4930
0.050
 Why?
Clinical Protocols
1
2023
258
0.050
 Why?
Ligands
1
2024
624
0.050
 Why?
RNA, Small Interfering
1
2024
586
0.050
 Why?
Chimerism
1
2021
29
0.050
 Why?
Lymphoid Tissue
1
2021
68
0.040
 Why?
Lymphocyte Subsets
1
2021
86
0.040
 Why?
Liver
1
2009
1846
0.040
 Why?
Mice, SCID
1
2021
349
0.040
 Why?
SEER Program
1
2021
208
0.040
 Why?
Hormones
1
2020
140
0.040
 Why?
Mice, Inbred NOD
1
2021
586
0.040
 Why?
M Phase Cell Cycle Checkpoints
1
2018
24
0.040
 Why?
Tissue Distribution
1
2018
297
0.040
 Why?
Infant, Newborn
1
2009
5741
0.040
 Why?
Anemia
1
2019
156
0.040
 Why?
Pregnancy
1
2009
6301
0.030
 Why?
Cetuximab
1
2016
94
0.030
 Why?
Retreatment
1
2016
69
0.030
 Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2016
116
0.030
 Why?
Neoplasm Transplantation
1
2016
259
0.030
 Why?
Drug Screening Assays, Antitumor
1
2016
197
0.030
 Why?
Platinum
1
2016
44
0.030
 Why?
Hematopoietic Stem Cell Transplantation
1
2021
578
0.030
 Why?
History, Ancient
1
2015
52
0.030
 Why?
Transcription Factors
1
2023
1649
0.030
 Why?
Proto-Oncogene Proteins p21(ras)
1
2016
265
0.030
 Why?
Databases, Genetic
1
2015
229
0.030
 Why?
DNA Damage
1
2017
379
0.030
 Why?
Mice, Knockout
1
2021
2811
0.030
 Why?
Biomarkers
2
2016
3923
0.030
 Why?
Opioid-Related Disorders
1
2021
506
0.030
 Why?
Phenotype
1
2021
3084
0.020
 Why?
Drug Combinations
1
2013
328
0.020
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2015
260
0.020
 Why?
Intracellular Signaling Peptides and Proteins
1
2015
431
0.020
 Why?
Immunohistochemistry
1
2016
1711
0.020
 Why?
Biopsy, Needle
1
2011
192
0.020
 Why?
Cohort Studies
1
2021
5431
0.020
 Why?
Transcription, Genetic
1
2017
1415
0.020
 Why?
HT29 Cells
1
2010
36
0.020
 Why?
Enzyme Inhibitors
1
2014
832
0.020
 Why?
Proto-Oncogene Proteins
1
2014
645
0.020
 Why?
Protein-Tyrosine Kinases
1
2013
429
0.020
 Why?
ErbB Receptors
1
2013
611
0.020
 Why?
Ki-67 Antigen
1
2010
109
0.020
 Why?
Capillary Permeability
1
2010
141
0.020
 Why?
Patient Selection
1
2013
678
0.020
 Why?
Follow-Up Studies
1
2018
4961
0.020
 Why?
Patient Satisfaction
1
2013
647
0.020
 Why?
Positron-Emission Tomography
1
2010
285
0.020
 Why?
Membrane Proteins
1
2015
1121
0.020
 Why?
Algorithms
1
2015
1638
0.020
 Why?
Magnetic Resonance Imaging
1
2019
3380
0.020
 Why?
Tomography, X-Ray Computed
1
2016
2551
0.020
 Why?
Adolescent
1
2024
20374
0.010
 Why?
Brain
1
2014
2629
0.010
 Why?
Young Adult
1
2014
12404
0.010
 Why?
Diamond's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (284) concept(s)
_
Co-Authors Expand Description
See all (67) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)